Characteristics of 10 Patients With Small Noncleaved Lymphoma
| . | . | % . |
|---|---|---|
| Age, (yr) | ||
| Median | 38 | |
| Range | 22.5-56 | |
| M:F | 7:3 | |
| Stage | ||
| IIE | 1 | |
| IIIE | 1 | |
| IV | 8 | |
| LDH | ||
| Elevated | 8 | 80 |
| Normal | 2 | 20 |
| ECOG | ||
| PS2 | 4 | 40 |
| PS3 | 6 | 60 |
| Bulky DS ≥10 cm | 8 | 80 |
| Extranodal sites | 10 | 100 |
| ≥2 sites | 8 | 80 |
| Age-adjusted IPI | ||
| High | ||
| 9 | 90 | |
| High-intermediate | 1 | 10 |
| Prior chemotherapy | Vanderbilt 4, CHOP + HD MTX 3, MACOP-B 2, CHOP-Bleo 1 | |
| Status at BMT | ||
| 1 CR | 7 | 70 |
| 1 PR | 3 | 30 |
| . | . | % . |
|---|---|---|
| Age, (yr) | ||
| Median | 38 | |
| Range | 22.5-56 | |
| M:F | 7:3 | |
| Stage | ||
| IIE | 1 | |
| IIIE | 1 | |
| IV | 8 | |
| LDH | ||
| Elevated | 8 | 80 |
| Normal | 2 | 20 |
| ECOG | ||
| PS2 | 4 | 40 |
| PS3 | 6 | 60 |
| Bulky DS ≥10 cm | 8 | 80 |
| Extranodal sites | 10 | 100 |
| ≥2 sites | 8 | 80 |
| Age-adjusted IPI | ||
| High | ||
| 9 | 90 | |
| High-intermediate | 1 | 10 |
| Prior chemotherapy | Vanderbilt 4, CHOP + HD MTX 3, MACOP-B 2, CHOP-Bleo 1 | |
| Status at BMT | ||
| 1 CR | 7 | 70 |
| 1 PR | 3 | 30 |
Abbreviations: Vanderbilt, cyclophosphamide, Etoposide, vincristine, Bleomycin, methotrexate, Doxorubicin, prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; MACOP-B, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and Bleomycin; CHOP-Bleo, CHOP + Bleomycin.